PRINCETON, N.J., Feb. 10 /PRNewswire/ -- BullMarket.com (http://www.bullmarket.com), an online investment newsletter focused on long-term growth and income-generating stocks, has provided subscribers with coverage of stem cell stocks, including Geron (Nasdaq: GERN), Osiris Therapeutics (Nasdaq: OSIR), Cytori Therapeutics (Nasdaq: CYTX), and StemCells (Nasdaq: STEM).
All paid and trial subscribers to BullMarket.com can now receive immediate access to the newsletter's exclusive daily reports. As a subscriber, you'll also gain access to our Recommended List of stocks, which outperformed the S&P 500 by 15% in 2008.
Start your 14-day free trial today:
BullMarket.com looked at the following topics, among others:
-- Can stem cell stocks continue their momentum?
-- What are some common misconceptions surrounding stem cell stocks?
-- What are some of the positives Osiris has going for it?
-- What potential problem could Cytori run into?
-- Which stock is best positioned to take advantage of increased interest and funding for embryonic stem cell research?
Launched in 1997, BullMarket.com has a strong track record of creating wealth for its subscribers by providing sound, long-term investing advice. The BullMarket.com Recommended List includes about 50 companies across all major industries, including Financials, Healthcare, Energy, Technology, and Retail, among others. BullMarket.com is one of the oldest continuously published investment newsletters online, and its Recommended List has consistently outperformed the major market indices.
NOTE: This release was published by Indie Research Advisors, LLC, a registered investment advisor with CRD #131926. Interested parties may visit adviserinfo.sec.gov for additional information. Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Contact: Marcie Martin, Bull Market Report, +1-888-278-5515
|SOURCE Indie Research Advisors, LLC|
Copyright©2009 PR Newswire.
All rights reserved